MedTrace Logo

A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults

NCT03713086 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2024-12-19

Study results available
· View outcomes & findings →

Summary

The primary objective of this clinical study is to assess the safety, and reactogenicity of CV7202 mRNA-rabies vaccine in healthy adults. Immunogenicity is also assessed.

Conditions

  • Rabies

Interventions

BIOLOGICAL

Rabipur®

3 doses administered IM at Days 1, 8 and 29 in the deltoid region of the arm

BIOLOGICAL

Rabies mRNA vaccine CV7202

CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm

BIOLOGICAL

Rabies mRNA vaccine CV7202

CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm

BIOLOGICAL

Rabies mRNA vaccine CV7202

CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm

Sponsors & Collaborators

  • CureVac

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-12
Primary Completion
2021-11-23
Completion
2021-11-23

Countries

  • Belgium
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03713086 on ClinicalTrials.gov